CTS Corporation (CTS) SEC Filings & Earnings Calls
EquiReason read 19 CTS Corporation SEC filings in the last 12 months. Latest: SC 13D/A on 2026-08-05 — Gabelli-related entities filed a Schedule 13D disclosing a 5.75% passive stake in CTS Corp, with no activist intent and recent small sales..
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 1.5B
- P/E TTM
- 22.3
- Dividend yield
- 0.3%
- 52-week
- —
- Next earnings
- 27 Oct, in 3 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
5 Aug 2026SC 13D/AGabelli-related entities filed a Schedule 13D disclosing a 5.75% passive stake in CTS Corp, with no activist intent and recent small sales.open
Figures in the filing · each found in the filing text
| Beneficial ownership percentage · 2026-08-04 | 5.8% |
5 Aug 2026SC 13D/AGabelli-related entities filed a Schedule 13D disclosing a 5.75% passive stake in CTS Corp, with no activist intent and recent small sales.open
Figures in the filing · each found in the filing text
| Beneficial ownership percentage · 2026-08-04 | 5.8% |
28 Jul 20268-K · 7.01LTM Revenue $564M; LTM Adj. EBITDA Margin 24; LTM Adj. Diluted EPS $2.58open
Figures in the filing · each found in the filing text
| LTM Revenue · LTM | $564M | |
| LTM Adj. EBITDA Margin · LTM | 24.0% | |
| LTM Adj. Diluted EPS · LTM | $2.58 |
Risks flagged
No new risks identified; presentation contains forward-looking statements with standard cautionary language.
“Cautionary statement regarding forward-looking statements.” · word for word
28 Jul 202610-QCTS Corporation reported solid Q2 2026 results with revenue up 7% YoY, gross margin expansion of 270 bps, and EPS growth of 8.1%, driven by strong Medical and Industrial segment performance.earningsopen
Figures in the filing · each found in the filing text
| Net Sales · Q2-2026 | $145M | +7% y/y |
| Net Sales - Transportation · Transportation · Q2-2026 | $59M | -2% y/y |
| Net Sales - Industrial · Industrial · Q2-2026 | $40M | +16% y/y |
| Net Sales - Medical · Medical · Q2-2026 | $28M | +45% y/y |
| Net Sales - Aerospace & Defense · Aerospace & Defense · Q2-2026 | $18M | -15% y/y |
| Net Earnings · Q2-2026 | $19M | +3% y/y |
| Operating Cash Flow · H1-2026 | $51M | +16% y/y |
Risks flagged
Environmental Remediation Liability
“Remediation reserves of $16.5M as of June 30, 2026, including $6.7M for the Asheville Site settlement.”
Geographic Concentration Risk
“The company has significant international operations, with foreign currency translation adjustments of ($3.3M) in H1 2026.”
Restructuring Risk
“Restructuring charges of $480K in H1 2026 for workforce reduction and facility consolidation.”
28 Jul 20268-K · 2.02, 7.01Sales $145M (+7% y/y); Net income $19M (+4% y/y); Diluted EPS $0.66 (+6% y/y); Guidance: Sales guidance raised to $565-585M; adjusted EPS guidance raised to $2.55-$2.70earningsopen
Figures in the filing · each found in the filing text
| Sales · Q2-2026 | $145M | +7% y/y |
| Net income · Q2-2026 | $19M | +4% y/y |
| Diluted EPS · Q2-2026 | $0.66 | +6% y/y |
| Adjusted Gross margin · Q2-2026 | 41.5% | |
| Adjusted EBITDA margin · Q2-2026 | 25.4% | |
| Adjusted diluted EPS · Q2-2026 | $0.74 | +30% y/y |
| Operating cash flow · Q2-2026 | $33M | +18% y/y |
Guidance
Sales guidance raised to $565-585M; adjusted EPS guidance raised to $2.55-$2.70
Raised guidance on strong diversification and margin performance.
Risks flagged
Transportation market decline of 2% YoY; reliance on diversified markets for growth.
“Sales to the transportation market decreased 2%.” · word for word
25 Jun 20268-K · 5.02New CEO base salary $675,000.00; new CEO LTI award $2M; Executive Chairman base salary $625,000.00open
Figures in the filing · each found in the filing text
| new CEO base salary · FY2026 | $675000.00 | |
| new CEO LTI award · FY2026 | $2M | |
| Executive Chairman base salary · FY2026 | $625000.00 |
Risks flagged
Leadership transition risk is low due to internal promotion and continued involvement of former CEO.
“New CEO was COO since Dec 2025; outgoing CEO remains Executive Chairman.”
29 Apr 20268-K · 2.02, 7.01Sales $139M (+11% y/y); Net income $17M (+31% y/y); Diluted EPS $0.59 (+34% y/y); Guidance: Sales midpoint raised from $565M to $570M; adjusted EPS midpoint raised from $2.375 to $2.40earningsopen
Figures in the filing · each found in the filing text
| Sales · total · Q1-2026 | $139M | +11% y/y |
| Net income · total · Q1-2026 | $17M | +31% y/y |
| Diluted EPS · total · Q1-2026 | $0.59 | +34% y/y |
| Adjusted gross margin · total · Q1-2026 | 39.5% | |
| Adjusted EBITDA margin · total · Q1-2026 | 23.0% | |
| Adjusted diluted EPS · total · Q1-2026 | $0.62 | +41% y/y |
| Operating cash flow · total · Q1-2026 | $17M | +12% y/y |
Guidance
Sales midpoint raised from $565M to $570M; adjusted EPS midpoint raised from $2.375 to $2.40
CTS narrowed guidance upward, reflecting confidence in continued strong demand and margin expansion.
Risks flagged
Transportation market growth remains modest at 3%, indicating potential cyclical risk.
“Sales to the transportation market increased 3%.” · word for word
Forward-looking statements contain standard macroeconomic and operational risks; no new specific risks identified.
“Generic cautionary language; no company-specific risk updates.”
29 Apr 202610-QNet sales $139M (+11% y/y); Net earnings $17M (+29% y/y); Operating cash flow $17M (+12% y/y)open
Figures in the filing · each found in the filing text
| Net sales · Q1-2026 | $139M | +11% y/y |
| Net earnings · Q1-2026 | $17M | +29% y/y |
| Operating cash flow · Q1-2026 | $17M | +12% y/y |
| Transportation revenue · Transportation · Q1-2026 | $60M | +3% y/y |
| Industrial revenue · Industrial · Q1-2026 | $37M | +15% y/y |
| Medical revenue · Medical · Q1-2026 | $25M | +28% y/y |
| Aerospace & Defense revenue · Aerospace & Defense · Q1-2026 | $17M | +11% y/y |
29 Apr 20268-K · 7.01LTM Revenue $555M; LTM Adj. EBITDA Margin 23; LTM Adj. Diluted EPS $2.41open
Figures in the filing · each found in the filing text
| LTM Revenue · LTM Q1-2026 | $555M | |
| LTM Adj. EBITDA Margin · LTM Q1-2026 | 23.0% | |
| LTM Adj. Diluted EPS · LTM Q1-2026 | $2.41 |
Risks flagged
No new risk signals; presentation contains standard forward-looking cautionary language.
“Cautionary statement regarding forward-looking statements; no specific new risks.”
2 Apr 2026DEF 14AAnnual proxy statement disclosing executive compensation, governance, and 2025 financial results.open
Figures in the filing · each found in the filing text
| Revenue · FY2025 | $541M | +5% y/y |
| Operating Cash Flow · FY2025 | $102M | |
| Medical Segment Sales · Medical · FY2025 | $85M | +21% y/y |
| Aerospace & Defense Segment Sales · Aerospace & Defense · FY2025 | $83M | +20% y/y |
| Industrial Segment Sales · Industrial · FY2025 | $140M | +12% y/y |
| Transportation Segment Sales · Transportation · FY2025 | $234M | -7% y/y |
| Total Booked Business · FY2025 | $1.00B | |
| Shareholder Returns · FY2025 | $62M | |
| Adjusted Diluted EPS · FY2025 | $2.23 | +5% y/y |
| Net Income · FY2025 | $64M | +10% y/y |
Risks flagged
Transportation Market Cyclicality
“Transportation sales were $234 million, down 7% compared to 2024, reflecting softer market conditions.” · word for word
Macroeconomic Uncertainty
“Despite mixed macroeconomic conditions, our teams executed well” · word for word
Supply Chain Disruption
“supply chain disruptions (including, but not limited to, the availability and cost of rare earth elements, minerals and metals)” · word for word
24 Feb 202610-KRisks named: Tariff and trade policy uncertainty, Rare earth supply dependency on China, Cyclical end-market exposure, Defense contract vulnerabilityopen
Risks flagged
Tariff and trade policy uncertainty
“During 2025, there were significant changes to tariffs by the U.S. and other countries.” · word for word
Rare earth supply dependency on China
“China is a predominant producer of these materials. China has in the past restricted export of certain of these materials.” · word for word
Cyclical end-market exposure
“We sell products to customers in cyclical industries that have experienced economic and industry downturns.” · word for word
Defense contract vulnerability
“These contracts may be suspended, canceled, or delayed, which could have an adverse impact on our revenues.” · word for word
10 Feb 20268-K · 7.01LTM Revenue $541M; LTM Adj. EBITDA Margin 23; LTM Adj. Diluted EPS $2.23open
Figures in the filing · each found in the filing text
| LTM Revenue · FY2025 | $541M | |
| LTM Adj. EBITDA Margin · FY2025 | 23.0% | |
| LTM Adj. Diluted EPS · FY2025 | $2.23 |
10 Feb 20268-K · 2.02, 7.01Sales $137M (+9% y/y); Net income $20M (+67% y/y); Diluted EPS $0.67 (+76% y/y); Guidance: FY2026 sales $550-$580M; Adj. diluted EPS $2.30-$2.45earningsopen
Figures in the filing · each found in the filing text
| Sales · Q4-2025 | $137M | +9% y/y |
| Net income · Q4-2025 | $20M | +67% y/y |
| Diluted EPS · Q4-2025 | $0.67 | +76% y/y |
| Adjusted Gross margin · Q4-2025 | 39.1% | |
| Adjusted EBITDA margin · Q4-2025 | 23.7% | |
| Adjusted diluted EPS · Q4-2025 | $0.62 | +24% y/y |
| Operating cash flow · Q4-2025 | $29M | +16% y/y |
| Full Year Sales · FY2025 | $541M | +5% y/y |
| Full Year Net income · FY2025 | $65M | +16% y/y |
| Full Year Diluted EPS · FY2025 | $2.19 | +22% y/y |
Guidance
FY2026 sales $550-$580M; Adj. diluted EPS $2.30-$2.45
CTS expects FY2026 sales of $550-$580M (midpoint $565M, +4.4% vs FY2025 $541M) and Adj. diluted EPS of $2.30-$2.45 (midpoint $2.375, +6.5% vs FY2025 $2.23), indicating continued growth and margin expansion.
Risks flagged
Transportation market sales declined 7% in FY2025, indicating cyclical weakness in that segment.
“Sales to the transportation end market decreased 7% in full year 2025.” · word for word
26 Nov 20258-K · 5.02Reported a director or officer change (departure, election, appointment or pay arrangement)open
Risks flagged
Departure of senior executive may cause short-term disruption, but appointment of internal candidate mitigates risk.
“Pratik Trivedi, Senior Vice President, has been appointed Chief Operating Officer (“COO”) of CTS effective December 5, 2025.” · word for word
24 Nov 20258-K · 1.01, 1.02, 2.03Entered a material definitive agreement (acquisition, partnership, or major contract); terminated a material definitive agreement, ending a significant contractopen
Risks flagged
Debt covenant compliance risk: net leverage ratio must not exceed 3.5x (or 4.25x post-acquisition) and interest coverage must be at least 3.0x.
“Credit Agreement requires that the Company maintain a net leverage ratio of not greater than 3.5 to 1.0 and to maintain an interest coverage ratio of not less than 3.0 to 1.” · word for word
28 Oct 202510-QCTS reported Q3 2025 results with 8% revenue growth driven by Aerospace & Defense, Industrial, and Medical segments, but net income declined due to higher expenses.earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q3-2025 | $143M | +8% y/y |
| Net Income · Q3-2025 | $14M | -24% y/y |
| Diluted EPS · Q3-2025 | $0.46 | -22% y/y |
| Gross Margin · Q3-2025 | 38.7% | |
| Operating Cash Flow · 9M-2025 | $73M | -1% y/y |
Risks flagged
Environmental Remediation Liability
“The Company has updated its estimate of potential exposure to be between $5,970 and $8,290. We have determined that no point within this range is more likely than another and, therefore, we have recorded a loss estimate of $5,970 as of September 30, 2025.” · word for word
Transportation Market Weakness
“Transportation $58,547 for the three months ended September 30, 2025 compared to $63,031 for the three months ended September 30, 2024.”
Restructuring Charges
“Restructuring charges $280 for the three months ended September 30, 2025.”
28 Oct 20258-K · 2.02, 7.01Sales $143M (+8% y/y); Net income $14M (-22% y/y); Diluted EPS $0.46 (-22% y/y); Guidance: FY2025 sales $535-$545M; adjusted diluted EPS $2.20-$2.25earningsopen
Figures in the filing · each found in the filing text
| Sales · Q3-2025 | $143M | +8% y/y |
| Net income · Q3-2025 | $14M | -22% y/y |
| Diluted EPS · Q3-2025 | $0.46 | -22% y/y |
| Adjusted diluted EPS · Q3-2025 | $0.60 | -2% y/y |
| Adjusted Gross margin · Q3-2025 | 38.9% | |
| Adjusted EBITDA margin · Q3-2025 | 23.8% | |
| Operating cash flow · Q3-2025 | $29M | -17% y/y |
Guidance
FY2025 sales $535-$545M; adjusted diluted EPS $2.20-$2.25
Guidance updated; sales midpoint $540M, EPS midpoint $2.225; no prior guidance provided for comparison, but implied cut given Q3 results and cautious outlook.
Risks flagged
Transportation end market decline continues; -7% YoY.
“Sales to the transportation end market decreased 7%.” · word for word
EPA past cost recovery claim resulted in $4.2M charge; potential for further environmental liabilities.
“Net income was $14 million, or 9.6% of sales, including an extraordinary $4.2 million charge related to the previously disclosed EPA past cost recovery claim.” · word for word
28 Oct 20258-K · 7.01LTM Revenue $531M; LTM Adjusted EBITDA Margin 23; LTM Adjusted Diluted EPS $2.11open
Figures in the filing · each found in the filing text
| LTM Revenue · LTM | $531M | |
| LTM Adjusted EBITDA Margin · LTM | 23.0% | |
| LTM Adjusted Diluted EPS · LTM | $2.11 |
Risks flagged
Tariff and geopolitical risks
“Forward-looking statements cite tariffs on China, Canada, Mexico, and geopolitical conflicts as risk factors”
Supply chain disruption risk
“Supply chain disruptions including availability of rare earth elements, minerals and metals”
CTS Corporation — questions
- What did CTS Corporation file recently?
- 19 SEC filings in the last 12 months. Latest: SC 13D/A on 2026-08-05 — Gabelli-related entities filed a Schedule 13D disclosing a 5.75% passive stake in CTS Corp, with no activist intent and recent small sales.
Every figure on this page comes from CTS Corporation's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.